ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH…
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales,…